Skip to main content

Table 1 The summary of GEO datasets used in the present study

From: HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia

GEO accession Number of samples patients subgroup Application in this study
GSE28654 [7] 89 61 M-CLL and 28 U-CLL WGCNA to reveal hub genes correlating with IGHV status
GSE38611 [8] 136 76 M-CLL and 60 U-CLL Validation for the correlation of hub gene expression with IGHV status
GSE40570 [11] 159 96 M-CLL vs 63 U-CLL Validation for the correlation of hub gene expression with IGHV status
GSE51529 [9] 229 131 M-CLL and 85 U-CLL Validation for the correlation of hub gene expression with IGHV status
GSE69034 144 86 M-CLL and 58 U-CLL Validation for the correlation of hub gene expression with IGHV status
GSE9992 [12] 60 24 M-CLL and 36 U-CLL Validation for the correlation of hub gene expression with IGHV status
GSE50006 210 188 CLL and 32 healthy donors Validation for expression difference of hub genes between CLL and healthy dornors
GSE32018 [23] 127 17 CLL, 23 FL, 22 DLBCL, 24 MCL, 15 MALT-MZL, 13 NMZL and 13 normal lymphoid tissues Validation for expression difference of hub genes between various type of lymphoid neoplasms
GSE58211 [13] 300 29 Binet stage A, 179 Binet stage B and 92 Binet stage C CLL patients Validation for expression difference of hub genes between different stages of CLL
GSE10138 [14] 68 32 progressive and 36 stable CLL patients Validation for the correlation of hub gene expression with treatment response in CLL patients
GSE103265 19 8 CLL and 11 Richter syndrome Validation for expression difference of hub genes between stable CLL and Richter syndrome patients
GSE39671 [15] 130 130 CLL survival analysis of TTFT stratificated by hub gene expression
GSE22762 [16] 107 107 CLL survival analysis of TTFT/OS stratificated by hub gene expression